Matrix Metalloproteinases: A challenging paradigm of cancer management

被引：180

作者：

Alaseem, Ali ^{[1
,2
,3
]}

Alhazzani, Khalid ^{[1
,2
,4
]}

Dondapati, Priya ^{[1
,2
]}

Alobid, Saad ^{[1
,2
,4
]}

Bishayee, Anupam ^{[5
]}

Rathinavelu, Appu ^{[1
,2
]}

机构：

[1] Nova Southeastern Univ, Rumbaugh Goodwin Inst Canc Res, Ft Lauderdale, FL 33314 USA

[2] Nova Southeastern Univ, Coll Pharm, Ft Lauderdale, FL 33328 USA

[3] Al Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi Arabia

[4] King Saud Univ, Coll Pharm, Riyadh, Saudi Arabia

[5] Lake Erie Coll Osteopath Med, Bradenton, FL 34211 USA

来源：

SEMINARS IN CANCER BIOLOGY | 2019年 / 56卷

关键词：

Matrix metalloproteinase; Cancer; Biomarker; Matrix metalloproteinase inhibitors; NF-KAPPA-B; TO-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; CELL LUNG-CANCER; HISTONE DEACETYLASE INHIBITOR; SKELETAL-RELATED EVENTS; IN-SITU HYBRIDIZATION; BREAST-CANCER; PROSTATE-CANCER; GENE-EXPRESSION;

D O I：

10.1016/j.semcancer.2017.11.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Matrix metalloproteinases (MMPs) are members of zinc-dependent endopeptidases implicated in a variety of physiological and pathological processes. Over the decades, MMPs have been studied for their role in cancer progression, migration, and metastasis. As a result, accumulated evidence of MMPs incriminating role has made them an attractive therapeutic target. Early generations of broad-spectrum MMP inhibitors exhibited potent inhibitory activities, which subsequently led to clinical trials. Unexpectedly, these trials failed to meet the desired goals, mainly due to the lack of efficacy, poor oral bioavailability, and toxicity. In this review, we discuss the regulatory role of MMPs in cancer progression, current strategies in targeting MMPs for cancer treatment including prodrug design and tumor imaging, and therapeutic value of MMPs as biomarkers in breast, lung, and prostate cancers.

引用

收藏

页码：100 / 115

页数：16

相关论文

共 279 条

[1] Analysis of the regulation of angiogenesis pathway by inhibiting MDM2 function in LNCaP-MST prostate cancer cells using PCR array [J].

Alaseem, Ali ;

Venkatesan, Thiagarajan ;

Alhazzani, Khalid ;

Rathinavelu, Appu .

CANCER RESEARCH, 2015, 75

[2] Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].

Albright, CF ;

Graciani, N ;

Han, W ;

Yue, E ;

Stein, R ;

Lai, ZH ;

Diamond, M ;

Dowling, R ;

Grimminger, L ;

Zhang, SY ;

Behrens, D ;

Musselman, A ;

Bruckner, R ;

Zhang, MZ ;

Jiang, X ;

Hu, D ;

Higley, A ;

DiMeo, S ;

Rafalski, M ;

Mandlekar, S ;

Car, B ;

Yeleswaram, S ;

Stern, A ;

Copeland, RA ;

Combs, A ;

Seitz, SP ;

Trainor, GL ;

Taub, R ;

Huang, P ;

Oliff, A .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760

[3] Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer [J].

Alpini, Gianfranco ;

Glaser, Shannon S. ;

Zhang, Jing-Ping ;

Francis, Heather ;

Han, Yuyan ;

Gong, Jiao ;

Stokes, Allison ;

Francis, Taylor ;

Hughart, Nathan ;

Hubble, Levi ;

Zhuang, Shi-Mei ;

Meng, Fanyin .

JOURNAL OF HEPATOLOGY, 2011, 55 (06) :1339-1345

[4] Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? [J].

Amin, Sic. Abdul ;

Adhikari, Nilanjan ;

Jha, Tarun .

PHARMACOLOGICAL RESEARCH, 2017, 122 :8-19

[5] The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis [J].

Andreuzzi, Eva ;

Colladel, Roberta ;

Pellicani, Rosanna ;

Tarticchio, Giulia ;

Cannizzaro, Renato ;

Spessotto, Paola ;

Bussolati, Benedetta ;

Brossa, Alessia ;

De Paoli, Paolo ;

Canzonieri, Vincenzo ;

Iozzo, Renato V. ;

Colombatti, Alfonso ;

Mongiat, Maurizio .

MATRIX BIOLOGY, 2017, 64 :40-53

[6] Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis [J].

Ardi, Veronica C. ;

Kupriyanova, Tatyana A. ;

Deryugina, Elena I. ;

Quigley, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) :20262-20267

[7] Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation [J].

Aviles, A. ;

Neri, N. ;

Huerta-Guzman, J. ;

Nambo, M. J. .

CURRENT ONCOLOGY, 2013, 20 (01) :E13-E20

[8] Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma [J].

Aviles, Agustin ;

Nambo, Maria J. ;

Neri, Natividad ;

Castaneda, Claudia ;

Cleto, Sergio ;

Huerta-Guzman, Judith .

MEDICAL ONCOLOGY, 2007, 24 (02) :227-230

[9] Ginkgolic Acid Inhibits Invasion and Migration and TGF--Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation [J].

Baek, Seung Ho ;

Ko, Jeong-Hyeon ;

Lee, Jong Hyun ;

Kim, Chulwon ;

Lee, Hanwool ;

Nam, Dongwoo ;

Lee, Junhee ;

Lee, Seok-Geun ;

Yang, Woong Mo ;

Um, Jae-Young ;

Sethi, Gautam ;

Ahn, Kwang Seok .

JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (02) :346-354

[10]

Beck A., 2010, 5 EUR ANT C 2009 NOV, P108

← 1 2 3 4 5 6 7 8 9 10 →